Cardiff Oncology (CRDF) vs Neumora Therapeutics (NMRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 11, 2026.
Summary
Cardiff Oncology (CRDF) has outperformed Neumora Therapeutics (NMRA) over the past year, losing 51.1% versus a loss of 75.6%. Neumora Therapeutics is the larger company by market cap ($89.4 million vs $84.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRDF | NMRA |
|---|---|---|
| Share price | $1.08 | $0.4757 |
| Market cap | $84.02M | $89.38M |
| 1-day change | +1.89% | -0.85% |
| YTD return | -61.57% | -73.42% |
| 1-year return | -51.13% | -75.61% |
| 5-year return | -83.13% | — |
| EPS (TTM) | $-0.60 | $-1.23 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.31 | $3.65 |
| 52-week low | $0.76 | $0.45 |
| Distance from 52-week high | -67.37% | -86.97% |
| Analyst consensus | none | none |
| Avg. price target upside | +437.96% | +1190.73% |
| Average volume | 1.04M | 1.19M |
| Shares outstanding | 77.80M | 187.90M |
| Employees | 30 | 63 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CRDF has outperformed NMRA by 24.5 percentage points over the past year.
About Cardiff Oncology
CRDF stock →Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 30 employees
About Neumora Therapeutics
NMRA stock →Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 63 employees
CRDF vs NMRA FAQ
Which is bigger, Cardiff Oncology or Neumora Therapeutics?
Neumora Therapeutics (NMRA) is larger, with a market capitalization of $89.38M compared with $84.02M for Cardiff Oncology (CRDF).
Which stock has performed better over the past year, CRDF or NMRA?
CRDF returned -51.13% over the past 12 months, compared with -75.61% for NMRA (price return, excluding dividends). Past performance does not predict future results.
Are Cardiff Oncology and Neumora Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.